

CFR Attachment A(8) - Physician Administered Drugs Oncology (Proposed to be effective September 1, 2024)

| TOS* | Procedure Code | Long Description | Modifier 1 | Age Range | Non-Facility (N)/ Facility | Provider Type/ Provider Specialty | CURRENT | | 9/1/2024 | | Percent Change from Current Medicaid |
|------|----------------|--|------------|-----------|----------------------------|-----------------------------------|----------------------|-------------------------------|-----------------------|--------------------------------|--------------------------------------|
| | | | | | | | Current Medicaid Fee | Current Adjusted Medicaid Fee | Proposed Medicaid Fee | Proposed Adjusted Medicaid Fee | |
| 9 | A9589 | instillation, hexaminolevulinate hcl, 100 mg | | 0-999 | N/F | | \$1,244.44 | \$1,244.44 | \$1,321.84 | \$1,321.84 | 6.22% |
| 1 | C9399 | unclassified drugs or biologicals | | 0-999 | F | | Manually Priced | Manually Priced | Manually Priced | Manually Priced | 0.00% |
| 1 | J0129 | injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | | 0-999 | N/F | | \$43.27 | \$43.27 | \$43.16 | \$43.16 | -0.25% |
| 1 | J0171 | injection, adrenalalin, epinephrine, 0.1 mg | | 0-999 | N/F | | \$0.73 | \$0.73 | \$0.75 | \$0.75 | 2.74% |
| 1 | J0208 | injection, sodium thiosulfate, 100 mg | | 0-999 | N/F | | \$109.60 | \$109.60 | \$109.60 | \$109.60 | 0.00% |
| 1 | J0461 | injection, atropine sulfate, 0.01 mg | | 0-999 | N/F | | \$0.09 | \$0.09 | \$0.08 | \$0.08 | -11.11% |
| 1 | J0600 | injection, edetate calcium disodium, up to 1000 mg | | 0-999 | N/F | | \$6,462.56 | \$6,462.56 | \$6,462.56 | \$6,462.56 | 0.00% |
| 1 | J0640 | injection, leucovorin calcium, per 50 mg | | 0-999 | N/F | | \$4.70 | \$4.70 | \$4.47 | \$4.47 | -4.89% |
| 1 | J0641 | injection, levoleucovorin, 0.5 mg | | 0-999 | N/F | | \$0.41 | \$0.41 | \$0.42 | \$0.42 | 2.44% |
| 1 | J0692 | injection, cefepime hydrochloride, 500 mg | | 0-999 | N/F | | \$1.23 | \$1.23 | \$1.26 | \$1.26 | 2.44% |
| 1 | J0696 | injection, ceftriaxone sodium, per 250 mg | | 0-999 | N/F | | \$0.57 | \$0.57 | \$0.49 | \$0.49 | -14.04% |
| 1 | J0713 | injection, ceftazidime, per 500 mg | | 0-999 | N/F | | \$1.84 | \$1.84 | \$1.69 | \$1.69 | -8.15% |
| 1 | J0743 | injection, cilastatin sodium; imipenem, per 250 mg | | 0-999 | N/F | | \$7.15 | \$7.15 | \$8.10 | \$8.10 | 13.29% |
| 1 | J0744 | injection, ciprofloxacin for intravenous infusion, 200 mg | | 0-999 | N/F | | \$1.09 | \$1.09 | \$1.09 | \$1.09 | 0.00% |
| 1 | J0780 | injection, prochlorperazine, up to 10 mg | | 0-999 | N/F | | \$3.01 | \$3.01 | \$3.43 | \$3.43 | 13.95% |
| 1 | J0881 | injection, darbepoetin alfa, 1 microgram (non-esrd use) | | 0-999 | N/F | | \$2.94 | \$2.94 | \$2.93 | \$2.93 | -0.34% |
| 1 | J0885 | injection, epoetin alfa, (for non-esrd use), 1000 units | | 0-999 | N/F | | \$6.88 | \$6.88 | \$6.88 | \$6.88 | 0.00% |
| 1 | J0885 | injection, epoetin alfa, (for non-esrd use), 1000 units | | 0-999 | F | 73 | \$6.88 | \$6.88 | \$6.88 | \$6.88 | 0.00% |
| 1 | J0893 | injection, decitabine (sun pharma) not therapeutically equivalent to J0894, 1 mg | | 0-999 | N/F | | \$2.24 | \$2.24 | \$2.24 | \$2.24 | 0.00% |
| 1 | J0894 | injection, decitabine, 1 mg | | 0-999 | N/F | | \$2.00 | \$2.00 | \$1.69 | \$1.69 | -15.50% |
| 1 | J0895 | injection, deferoxamine mesylate, 500 mg | | 0-999 | N/F | | \$8.59 | \$8.59 | \$8.60 | \$8.60 | 0.12% |
| 1 | J0897 | injection, denosumab, 1 mg | | 0-999 | N/F | | \$24.19 | \$24.19 | \$25.20 | \$25.20 | 4.18% |
| 1 | J1030 | injection, methylprednisolone acetate, 40 mg | | 0-999 | N/F | | \$7.61 | \$7.61 | \$6.42 | \$6.42 | -15.64% |
| 1 | J1040 | injection, methylprednisolone acetate, 80 mg | | 0-999 | N/F | | \$11.91 | \$11.91 | \$9.80 | \$9.80 | -17.72% |
| 1 | J1100 | injection, dexamethasone sodium phosphate, 1mg | | 0-999 | N/F | | \$0.12 | \$0.12 | \$0.12 | \$0.12 | 0.00% |
| 1 | J1120 | injection, acetazolamide sodium, up to 500 mg | | 0-999 | N/F | | \$29.70 | \$29.70 | \$28.12 | \$28.12 | -5.32% |
| 1 | J1170 | injection, hydromorphone, up to 4 mg | | 0-999 | N/F | | \$4.35 | \$4.35 | \$4.59 | \$4.59 | 5.52% |
| 1 | J1190 | injection, dexrazoxane hydrochloride, per 250 mg | | 0-999 | N/F | | \$113.90 | \$113.90 | \$108.01 | \$108.01 | -5.17% |
| 1 | J1200 | injection, diphenhydramine hcl, up to 50 mg | | 0-999 | N/F | | \$1.06 | \$1.06 | \$0.80 | \$0.80 | -24.53% |
| 1 | J1300 | injection, ecuzumab, 10 mg | | 0-999 | N/F | | \$225.79 | \$225.79 | \$225.69 | \$225.69 | -0.04% |
| 1 | J1410 | injection, erythromycin lactobionate, per 500 mg | | 0-999 | N/F | | \$371.89 | \$371.89 | \$372.15 | \$372.15 | 0.07% |
| 1 | J1442 | injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | | 0-999 | N/F | | \$0.99 | \$0.99 | \$0.99 | \$0.99 | 0.00% |
| 1 | J1448 | injection, trilaciclib, 1mg | | 0-999 | N/F | | \$5.10 | \$5.10 | \$5.20 | \$5.20 | 1.96% |

CFR Attachment A(8) - Physician Administered Drugs Oncology (Proposed to be effective September 1, 2024)

| TOS* | Procedure Code | Long Description | Modifier 1 | Age Range | Non-Facility (N)/ Facility | Provider Type/ Provider Specialty | CURRENT | | 9/1/2024 | | Percent Change from Current Medicaid |
|------|----------------|---|------------|-----------|----------------------------|-----------------------------------|----------------------|-------------------------------|-----------------------|--------------------------------|--------------------------------------|
| | | | | | | | Current Medicaid Fee | Current Adjusted Medicaid Fee | Proposed Medicaid Fee | Proposed Adjusted Medicaid Fee | |
| 1 | J1453 | injection, fosaprepitant, 1 mg | | 0-999 | N/F | | \$0.14 | \$0.14 | \$0.14 | \$0.14 | 0.00% |
| 1 | J1459 | injection, immune globulin (privigen), intravenous, non-lyophilized (e.g. liquid), 500 mg | | 0-999 | N/F | | \$47.99 | \$47.99 | \$48.29 | \$48.29 | 0.63% |
| 1 | J1561 | injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g. liquid), 500 mg | | 0-999 | N/F | | \$50.64 | \$50.64 | \$49.79 | \$49.79 | -1.68% |
| 1 | J1566 | injection, immune globulin, intravenous, lyophilized (e.g. powder), not otherwise specified, 500 mg | | 0-999 | N/F | | \$77.77 | \$77.77 | \$78.50 | \$78.50 | 0.94% |
| 1 | J1568 | injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g. liquid), 500 mg | | 0-999 | N/F | | \$44.12 | \$44.12 | \$44.98 | \$44.98 | 1.95% |
| 1 | J1569 | injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g. liquid), 500 mg | | 0-999 | N/F | | \$46.03 | \$46.03 | \$44.15 | \$44.15 | -4.08% |
| 1 | J1572 | injection, immune globulin, (flebogamma/flebogamma dif), intravenous, non-lyophilized (e.g. liquid), 500 mg | | 0-999 | N/F | | \$56.12 | \$56.12 | \$56.12 | \$56.12 | 0.00% |
| 1 | J1626 | injection, granisetron hydrochloride, 100 mcg | | 0-999 | N/F | | \$0.39 | \$0.39 | \$0.38 | \$0.38 | -2.56% |
| 1 | J1627 | injection, granisetron, extended-release, 0.1 mg | | 0-999 | N/F | | \$5.88 | \$5.88 | \$5.67 | \$5.67 | -3.57% |
| 1 | J1630 | injection, haloperidol, up to 5 mg | | 0-999 | N/F | | \$1.38 | \$1.38 | \$1.42 | \$1.42 | 2.90% |
| 1 | J1642 | injection, heparin sodium, (heparin lock flush), per 10 units | | 0-999 | N/F | | \$0.02 | \$0.02 | \$0.02 | \$0.02 | 0.00% |
| 1 | J1644 | injection, heparin sodium, per 1000 units | | 0-999 | N/F | | \$0.26 | \$0.26 | \$0.27 | \$0.27 | 3.85% |
| 1 | J1644 | injection, heparin sodium, per 1000 units | | 0-999 | N/F | 73 | \$0.26 | \$0.26 | \$0.27 | \$0.27 | 3.85% |
| 1 | J1645 | injection, dalteparin sodium, per 2500 iu | | 0-999 | N/F | | \$16.60 | \$16.60 | \$17.40 | \$17.40 | 4.82% |
| 1 | J1650 | injection, enoxaparin sodium, 10 mg | | 0-999 | N/F | | \$0.68 | \$0.68 | \$0.68 | \$0.68 | 0.00% |
| 1 | J1652 | injection, fondaparinux sodium, 0.5 mg | | 0-999 | N/F | | \$1.07 | \$1.07 | \$1.09 | \$1.09 | 1.87% |
| 1 | J1720 | injection, hydrocortisone sodium succinate, up to 100 mg | | 0-999 | N/F | | \$17.51 | \$17.51 | \$17.85 | \$17.85 | 1.94% |
| 1 | J1740 | injection, ibandronate sodium, 1 mg | | 0-999 | N/F | | \$29.31 | \$29.31 | \$25.60 | \$25.60 | -12.66% |
| 1 | J1750 | injection, iron dextran, 50 mg | | 0-999 | N/F | | \$17.18 | \$17.18 | \$17.32 | \$17.32 | 0.81% |
| 1 | J1756 | injection, iron sucrose, 1 mg | | 0-999 | N/F | | \$0.21 | \$0.21 | \$0.22 | \$0.22 | 4.76% |
| 1 | J1756 | injection, iron sucrose, 1 mg | | 0-999 | N/F | 72 | \$0.21 | \$0.21 | \$0.22 | \$0.22 | 4.76% |
| 1 | J1756 | injection, iron sucrose, 1 mg | | 0-999 | F | 73 | \$0.21 | \$0.21 | \$0.22 | \$0.22 | 4.76% |
| 1 | J1790 | injection, droperidol, up to 5 mg | | 0-999 | N/F | | \$10.74 | \$10.74 | \$10.74 | \$10.74 | 0.00% |
| 1 | J1930 | injection, lanreotide, 1 mg | | 0-999 | N/F | | \$54.18 | \$54.18 | \$48.44 | \$48.44 | -10.59% |
| 1 | J1940 | injection, furosemide, up to 20 mg | | 0-999 | N/F | | \$0.50 | \$0.50 | \$0.57 | \$0.57 | 14.00% |
| 1 | J1952 | leuprolide injectable, camcevi, 1 mg | | 0-999 | N/F | | \$78.31 | \$78.31 | \$59.80 | \$59.80 | -23.64% |
| 1 | J1954 | injection, leuprolide acetate for depot suspension (cipra), 7.5 mg | | 0-999 | N/F | | \$542.03 | \$542.03 | \$355.28 | \$355.28 | -34.45% |
| 1 | J1956 | injection, levofloxacin, 250 mg | | 0-999 | N/F | | \$0.92 | \$0.92 | \$0.91 | \$0.91 | -1.09% |
| D | J1956 | injection, levofloxacin, 250 mg | | 0-999 | N | | \$0.92 | \$0.92 | \$0.91 | \$0.91 | -1.09% |
| 1 | J2060 | injection, lorazepam, 2 mg | | 0-999 | N/F | | \$0.85 | \$0.85 | \$0.85 | \$0.85 | 0.00% |
| 1 | J2150 | injection, mannitol, 25% in 50 ml | | 0-999 | N/F | | \$4.93 | \$4.93 | \$4.93 | \$4.93 | 0.00% |
| 1 | J2150 | injection, mannitol, 25% in 50 ml | | 0-999 | N/F | 73 | \$4.93 | \$4.93 | \$4.93 | \$4.93 | 0.00% |
| 1 | J2175 | injection, meperidine hydrochloride, per 100 mg | | 0-999 | N/F | | \$7.31 | \$7.31 | \$7.30 | \$7.30 | -0.14% |

CFR Attachment A(8) - Physician Administered Drugs Oncology (Proposed to be effective September 1, 2024)

| TOS* | Procedure Code | Long Description | Modifier 1 | Age Range | Non-Facility (N)/ Facility | Provider Type/ Provider Specialty | CURRENT | | 9/1/2024 | | Percent Change from Current Medicaid |
|------|----------------|--|------------|-----------|----------------------------|-----------------------------------|----------------------|-------------------------------|-----------------------|--------------------------------|--------------------------------------|
| | | | | | | | Current Medicaid Fee | Current Adjusted Medicaid Fee | Proposed Medicaid Fee | Proposed Adjusted Medicaid Fee | |
| 1 | J2250 | injection, midazolam hydrochloride, per 1 mg | | 0-999 | N/F | | \$0.14 | \$0.14 | \$0.14 | \$0.14 | 0.00% |
| 1 | J2251 | injection, midazolam hydrochloride (wg critical care) not therapeutically equivalent to J2250, per 1 mg | | 0-999 | N/F | | \$0.29 | \$0.29 | \$0.28 | \$0.28 | -3.45% |
| 1 | J2270 | injection, morphine sulfate, up to 10 mg | | 0-999 | N/F | | \$4.60 | \$4.60 | \$4.67 | \$4.67 | 1.52% |
| 1 | J2310 | injection, naloxone hydrochloride, per 1 mg | | 0-999 | N/F | | \$9.45 | \$9.45 | \$7.29 | \$7.29 | -22.86% |
| 1 | J2354 | injection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcg | | 0-999 | N/F | | \$1.31 | \$1.31 | \$1.19 | \$1.19 | -9.16% |
| 1 | J2355 | injection, oprelvekin, 5 mg | | 0-999 | N/F | | \$528.92 | \$528.92 | \$528.92 | \$528.92 | 0.00% |
| 1 | J2405 | injection, ondansetron hydrochloride, per 1 mg | | 0-999 | N/F | | \$0.11 | \$0.11 | \$0.10 | \$0.10 | -9.09% |
| 1 | J2430 | injection, pamidronate disodium, per 30 mg | | 0-999 | N/F | | \$10.32 | \$10.32 | \$8.87 | \$8.87 | -14.05% |
| 1 | J2469 | injection, palonosetron hcl, 25 mcg | | 0-999 | N/F | | \$1.00 | \$1.00 | \$0.85 | \$0.85 | -15.00% |
| 1 | J2506 | injection, pegfilgrastim, excludes biosimilar, 0.5 mg | | 0-999 | N/F | | \$85.71 | \$85.71 | \$50.68 | \$50.68 | -40.87% |
| 1 | J2545 | pentamidine isethionate, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per 300 mg | | 0-999 | N/F | | \$93.86 | \$93.86 | \$93.86 | \$93.86 | 0.00% |
| 1 | J2550 | injection, promethazine hcl, up to 50 mg | | 0-999 | N/F | | \$3.15 | \$3.15 | \$3.59 | \$3.59 | 13.97% |
| 1 | J2597 | injection, desmopressin acetate, per 1 mcg | | 0-999 | N/F | | \$7.27 | \$7.27 | \$6.33 | \$6.33 | -12.93% |
| 1 | J2765 | injection, metoclopramide hcl, up to 10 mg | | 0-999 | N/F | | \$1.24 | \$1.24 | \$1.09 | \$1.09 | -12.10% |
| 1 | J2792 | injection, rho d immune globulin, intravenous, human, solvent detergent, 100 iu | | 0-999 | N/F | | \$33.71 | \$33.71 | \$32.96 | \$32.96 | -2.22% |
| 1 | J2796 | injection, romiplostim, 10 micrograms | | 0-999 | N/F | | \$95.47 | \$95.47 | \$96.03 | \$96.03 | 0.59% |
| 1 | J2820 | injection, sargamostim (gm-csf), 50 mcg | | 0-999 | N/F | | \$58.31 | \$58.31 | \$59.32 | \$59.32 | 1.73% |
| 1 | J2916 | injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | | 0-999 | N/F | | \$2.12 | \$2.12 | \$2.37 | \$2.37 | 11.79% |
| 1 | J2916 | injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | | 0-999 | N/F | 72 | \$2.12 | \$2.12 | \$2.37 | \$2.37 | 11.79% |
| 1 | J2916 | injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | | 0-999 | F | 73 | \$2.12 | \$2.12 | \$2.37 | \$2.37 | 11.79% |
| 1 | J2920 | injection, methylprednisolone sodium succinate, up to 40 mg | | 0-999 | N/F | | \$4.24 | \$4.24 | \$4.19 | \$4.19 | -1.18% |
| 1 | J2930 | injection, methylprednisolone sodium succinate, up to 125 mg | | 0-999 | N/F | | \$5.73 | \$5.73 | \$5.88 | \$5.88 | 2.62% |
| 1 | J2997 | injection, alteplase recombinant, 1 mg | | 0-999 | N/F | | \$89.15 | \$89.15 | \$88.97 | \$88.97 | -0.20% |
| 1 | J2997 | injection, alteplase recombinant, 1 mg | | 0-999 | F | 73 | \$89.15 | \$89.15 | \$88.97 | \$88.97 | -0.20% |
| 1 | J3010 | injection, fentanyl citrate, 0.1 mg | | 0-999 | N/F | | \$0.84 | \$0.84 | \$0.97 | \$0.97 | 15.48% |
| 1 | J3240 | injection, thyrotropin alpha, 0.9 mg, provided in 1.1 mg vial | | 0-999 | N/F | | \$2,001.49 | \$2,001.49 | \$2,021.17 | \$2,021.17 | 0.98% |
| 1 | J3315 | injection, triptorelin pamoate, 3.75 mg | | 0-999 | N/F | | \$382.39 | \$382.39 | \$413.59 | \$413.59 | 8.16% |
| 1 | J3316 | injection, triptorelin, extended-release, 3.75 mg | | 0-999 | N/F | | \$3,747.31 | \$3,747.31 | \$3,747.31 | \$3,747.31 | 0.00% |
| 1 | J3360 | injection, diazepam, up to 5 mg | | 0-999 | N/F | | \$5.25 | \$5.25 | \$5.47 | \$5.47 | 4.19% |
| 1 | J3370 | injection, vancomycin hcl, 500 mg | | 0-999 | N/F | | \$2.41 | \$2.41 | \$2.31 | \$2.31 | -4.15% |
| 1 | J3370 | injection, vancomycin hcl, 500 mg | | 0-999 | F | 73 | \$2.41 | \$2.41 | \$2.31 | \$2.31 | -4.15% |

CFR Attachment A(8) - Physician Administered Drugs Oncology (Proposed to be effective September 1, 2024)

| TOS* | Procedure Code | Long Description | Modifier 1 | Age Range | Non-Facility (N)/ Facility | Provider Type/ Provider Specialty | CURRENT | | 9/1/2024 | | Percent Change from Current Medicaid |
|------|----------------|---|------------|-----------|----------------------------|-----------------------------------|----------------------|-------------------------------|-----------------------|--------------------------------|--------------------------------------|
| | | | | | | | Current Medicaid Fee | Current Adjusted Medicaid Fee | Proposed Medicaid Fee | Proposed Adjusted Medicaid Fee | |
| 1 | J3420 | injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | | 0-999 | N/F | | \$1.31 | \$1.31 | \$1.44 | \$1.44 | 9.92% |
| 1 | J3430 | injection, phytonadione (vitamin k), per 1 mg | | 0-999 | N/F | | \$2.87 | \$2.87 | \$2.90 | \$2.90 | 1.05% |
| 1 | J3470 | injection, hyaluronidase, up to 150 units | | 0-999 | N/F | | \$66.96 | \$66.96 | \$66.96 | \$66.96 | 0.00% |
| 1 | J3475 | injection, magnesium sulfate, per 500 mg | | 0-999 | N/F | | \$0.93 | \$0.93 | \$0.69 | \$0.69 | -25.81% |
| 1 | J3480 | injection, potassium chloride, per 2 meq | | 0-999 | N/F | | \$0.10 | \$0.10 | \$0.12 | \$0.12 | 20.00% |
| 1 | J3490 | unclassified drugs | | 0-999 | N/F | | Manually Priced | Manually Priced | Manually Priced | Manually Priced | 0.00% |
| 1 | J7040 | infusion, normal saline solution, sterile (500 ml= 1 unit) | | 0-999 | N/F | | \$1.27 | \$1.27 | \$1.35 | \$1.35 | 6.30% |
| 1 | J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | | 0-999 | N/F | | \$1.18 | \$1.18 | \$1.59 | \$1.59 | 34.75% |
| 1 | J7050 | infusion, normal saline solution , 250 cc | | 0-999 | N/F | | \$0.64 | \$0.64 | \$0.67 | \$0.67 | 4.69% |
| 1 | J7060 | 5% dextrose/water (500 ml = 1 unit) | | 0-999 | N/F | | \$1.81 | \$1.81 | \$1.93 | \$1.93 | 6.63% |
| 1 | J7070 | infusion, d5w, 1000 cc | | 0-999 | N/F | | \$3.62 | \$3.62 | \$3.86 | \$3.86 | 6.63% |
| 1 | J7187 | injection, von willebrand factor complex (humate-p), per iu vwfr:co | | 0-999 | N/F | | \$1.35 | \$1.35 | \$1.35 | \$1.35 | 0.00% |
| 1 | J7308 | aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | | 0-999 | N/F | | \$391.23 | \$391.23 | \$392.32 | \$392.32 | 0.28% |
| 1 | J9000 | injection, doxorubicin hydrochloride, 10 mg | | 0-999 | N/F | | \$2.50 | \$2.50 | \$2.50 | \$2.50 | 0.00% |
| 1 | J9017 | injection, arsenic trioxide, 1 mg | | 0-999 | N/F | | \$12.97 | \$12.97 | \$15.78 | \$15.78 | 21.67% |
| 1 | J9019 | injection, asparaginase (erwinaze), 1,000 iu | | 0-999 | N/F | | \$483.70 | \$483.70 | \$483.70 | \$483.70 | 0.00% |
| 1 | J9021 | injection, asparaginase, recombinant, (rylaze), 0.1 mg | | 0-999 | N/F | | \$49.53 | \$49.53 | \$50.96 | \$50.96 | 2.89% |
| 1 | J9022 | injection, atezolizumab, 10 mg | | 0-999 | N/F | | \$82.68 | \$82.68 | \$85.01 | \$85.01 | 2.82% |
| 1 | J9023 | injection, avelumab, 10 mg | | 0-999 | N/F | | \$90.57 | \$90.57 | \$92.37 | \$92.37 | 1.99% |
| 1 | J9025 | injection, azacitidine, 1 mg | | 0-999 | N/F | | \$0.40 | \$0.40 | \$0.35 | \$0.35 | -12.50% |
| 1 | J9030 | bcg live intravesical instillation, 1 mg | | 0-999 | N/F | | \$2.89 | \$2.89 | \$2.89 | \$2.89 | 0.00% |
| 1 | J9032 | injection, belinostat, 10 mg | | 0-999 | N/F | | \$47.62 | \$47.62 | \$48.88 | \$48.88 | 2.65% |
| 1 | J9033 | injection, bendamustine hcl (treanda), 1 mg | | 0-999 | N/F | | \$12.28 | \$12.28 | \$9.19 | \$9.19 | -25.16% |
| 1 | J9034 | injection, bendamustine hcl (bendeka), 1 mg | | 0-999 | N/F | | \$16.51 | \$16.51 | \$14.76 | \$14.76 | -10.60% |
| 1 | J9035 | injection, bevacizumab, 10 mg | | 0-999 | N/F | | \$73.58 | \$73.58 | \$74.07 | \$74.07 | 0.67% |
| 1 | J9036 | injection, bendamustine hydrochloride, (belrapzo), 1 mg | | 0-999 | N/F | | \$16.72 | \$16.72 | \$13.09 | \$13.09 | -21.71% |
| 1 | J9040 | injection, bleomycin sulfate, 15 units | | 0-999 | N/F | | \$24.53 | \$24.53 | \$21.02 | \$21.02 | -14.31% |
| 1 | J9041 | injection, bortezomib, 0.1 mg | | 0-999 | N/F | | \$3.03 | \$3.03 | \$1.96 | \$1.96 | -35.31% |
| 1 | J9042 | injection, brentuximab vedotin, 1 mg | | 0-999 | N/F | | \$221.96 | \$221.96 | \$230.61 | \$230.61 | 3.90% |
| 1 | J9043 | injection, cabazitaxel, 1 mg | | 0-999 | N/F | | \$206.03 | \$206.03 | \$210.45 | \$210.45 | 2.15% |
| 1 | J9045 | injection, carboplatin, 50 mg | | 0-999 | N/F | | \$2.41 | \$2.41 | \$3.60 | \$3.60 | 49.38% |
| 1 | J9046 | injection, bortezomib, (dr. reddy's), not therapeutically equivalent to j9041, 0.1 mg | | 0-999 | N/F | | \$10.96 | \$10.96 | \$8.57 | \$8.57 | -21.81% |
| 1 | J9047 | injection, carfilzomib, 1 mg | | 0-999 | N/F | | \$47.04 | \$47.04 | \$47.09 | \$47.09 | 0.11% |
| 1 | J9048 | injection, bortezomib (fresenius kabi), not therapeutically equivalent to j9041, 0.1 mg | | 0-999 | N/F | | \$10.29 | \$10.29 | \$10.29 | \$10.29 | 0.00% |
| 1 | J9049 | injection, bortezomib (hospira), not therapeutically equivalent to j9041, 0.1 mg | | 0-999 | N/F | | \$3.89 | \$3.89 | \$1.52 | \$1.52 | -60.93% |
| 1 | J9050 | injection, carmustine, 100 mg | | 0-999 | N/F | | \$245.96 | \$245.96 | \$271.47 | \$271.47 | 10.37% |
| 1 | J9055 | injection, cetuximab, 10 mg | | 0-999 | N/F | | \$72.08 | \$72.08 | \$73.72 | \$73.72 | 2.28% |

CFR Attachment A(8) - Physician Administered Drugs Oncology (Proposed to be effective September 1, 2024)

| TOS* | Procedure Code | Long Description | Modifier 1 | Age Range | Non-Facility (N)/ Facility | Provider Type/ Provider Specialty | CURRENT | | 9/1/2024 | | Percent Change from Current Medicaid |
|------|----------------|--|------------|-----------|----------------------------|-----------------------------------|----------------------|-------------------------------|-----------------------|--------------------------------|--------------------------------------|
| | | | | | | | Current Medicaid Fee | Current Adjusted Medicaid Fee | Proposed Medicaid Fee | Proposed Adjusted Medicaid Fee | |
| 1 | J9056 | injection, bendamustine hydrochloride (vivimusta), 1 mg | | 0-999 | N/F | | \$33.33 | \$33.33 | \$33.45 | \$33.45 | 0.36% |
| 1 | J9057 | injection, copanlisib, 1 mg | | 0-999 | N/F | | \$100.99 | \$100.99 | \$103.01 | \$103.01 | 2.00% |
| 1 | J9059 | injection, bendamustine hydrochloride (baxter), 1 mg | | 0-999 | N/F | | \$23.96 | \$23.96 | \$20.78 | \$20.78 | -13.27% |
| 1 | J9060 | injection, cisplatin, powder or solution, 10 mg | | 0-999 | N/F | | \$3.17 | \$3.17 | \$4.04 | \$4.04 | 27.44% |
| 1 | J9061 | injection, amivantamab-vmjw, 2 mg | | 0-999 | N/F | | \$19.63 | \$19.63 | \$19.98 | \$19.98 | 1.78% |
| 1 | J9063 | injection, mirvetuximab soravtansine-gynx, 1 mg | | 0-999 | N/F | | \$65.80 | \$65.80 | \$65.71 | \$65.71 | -0.14% |
| 1 | J9065 | injection, cladribine, per 1 mg | | 0-999 | N/F | | \$18.30 | \$18.30 | \$15.77 | \$15.77 | -13.83% |
| 1 | J9070 | cyclophosphamide, 100 mg | | 0-999 | N/F | | \$17.09 | \$17.09 | \$20.50 | \$20.50 | 19.95% |
| 1 | J9071 | injection, cyclophosphamide, (auromedics), 5 mg | | 0-999 | N/F | | \$3.87 | \$3.87 | \$3.87 | \$3.87 | 0.00% |
| 1 | J9100 | injection, cytarabine, 100 mg | | 0-999 | N/F | | \$0.92 | \$0.92 | \$0.97 | \$0.97 | 5.43% |
| 1 | J9118 | injection, calaspargase pegol-mknl, 10 units | | 0-999 | N/F | | \$72.87 | \$72.87 | \$72.88 | \$72.88 | 0.01% |
| 1 | J9119 | injection, cemiplimab-rwlc, 1 mg | | 0-999 | N/F | | \$26.92 | \$26.92 | \$27.46 | \$27.46 | 2.01% |
| 1 | J9120 | injection, dactinomycin, 0.5 mg | | 0-999 | N/F | | \$594.55 | \$594.55 | \$668.90 | \$668.90 | 12.51% |
| 1 | J9130 | dacarbazine, 100 mg | | 0-999 | N/F | | \$4.05 | \$4.05 | \$3.73 | \$3.73 | -7.90% |
| 1 | J9144 | injection, daratumumab, 10 mg and hyaluronidase-fihj | | 0-999 | N/F | | \$49.12 | \$49.12 | \$49.05 | \$49.05 | -0.14% |
| 1 | J9145 | injection, daratumumab, 10 mg | | 0-999 | N/F | | \$61.78 | \$61.78 | \$61.71 | \$61.71 | -0.11% |
| 1 | J9150 | injection, daunorubicin, 10 mg | | 0-999 | N/F | | \$45.62 | \$45.62 | \$35.67 | \$35.67 | -21.81% |
| 1 | J9153 | injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine | | 0-999 | N/F | | \$227.23 | \$227.23 | \$231.76 | \$231.76 | 1.99% |
| 1 | J9155 | injection, degarelix, 1 mg | | 0-999 | N/F | | \$4.19 | \$4.19 | \$4.19 | \$4.19 | 0.00% |
| 1 | J9171 | injection, docetaxel, 1 mg | | 0-999 | N/F | | \$0.58 | \$0.58 | \$0.58 | \$0.58 | 0.00% |
| 1 | J9173 | injection, durvalumab, 10 mg | | 0-999 | N/F | | \$79.76 | \$79.76 | \$80.71 | \$80.71 | 1.19% |
| 1 | J9176 | injection, elotuzumab, 1 mg | | 0-999 | N/F | | \$7.19 | \$7.19 | \$7.38 | \$7.38 | 2.64% |
| 1 | J9177 | injection, enfortumab vedotin-ejfv, 0.25 mg | | 0-999 | N/F | | \$33.82 | \$33.82 | \$35.03 | \$35.03 | 3.58% |
| 1 | J9178 | injection, epirubicin hcl, 2 mg | | 0-999 | N/F | | \$1.34 | \$1.34 | \$1.38 | \$1.38 | 2.99% |
| 1 | J9179 | injection, eribulin mesylate, 0.1 mg | | 0-999 | N/F | | \$128.78 | \$128.78 | \$134.02 | \$134.02 | 4.07% |
| 1 | J9181 | injection, etoposide, 10 mg | | 0-999 | N/F | | \$0.70 | \$0.70 | \$0.70 | \$0.70 | 0.00% |
| 1 | J9185 | injection, fludarabine phosphate, 50 mg | | 0-999 | N/F | | \$604.75 | \$604.75 | \$173.97 | \$173.97 | -71.23% |
| 1 | J9190 | injection, fluorouracil, 500 mg | | 0-999 | N/F | | \$1.83 | \$1.83 | \$1.83 | \$1.83 | 0.00% |
| 1 | J9196 | injection, gemcitabine hydrochloride (accord), not therapeutically equivalent to J9201, 200 mg | | 0-999 | N/F | | \$3.85 | \$3.85 | \$3.85 | \$3.85 | 0.00% |
| 1 | J9198 | injection, gemcitabine hydrochloride, (infugem), 100 mg | | 0-999 | N/F | | \$27.29 | \$27.29 | \$27.29 | \$27.29 | 0.00% |
| 1 | J9200 | injection, floxuridine, 500 mg | | 0-999 | N/F | | \$3,551.00 | \$3,551.00 | \$3,722.04 | \$3,722.04 | 4.82% |
| 1 | J9201 | injection, gemcitabine hcl, not otherwise specified, 200 mg | | 0-999 | N/F | | \$3.71 | \$3.71 | \$3.65 | \$3.65 | -1.62% |
| 1 | J9203 | injection, gemtuzumab ozogamicin, 0.1 mg | | 0-999 | N/F | | \$221.84 | \$221.84 | \$226.28 | \$226.28 | 2.00% |
| 1 | J9204 | injection, mogamulizumab-kpkc, 1 mg | | 0-999 | N/F | | \$226.71 | \$226.71 | \$234.17 | \$234.17 | 3.29% |
| 1 | J9205 | injection, irinotecan liposome, 1 mg | | 0-999 | N/F | | \$61.96 | \$61.96 | \$62.02 | \$62.02 | 0.10% |
| 1 | J9206 | injection, irinotecan, 20 mg | | 0-999 | N/F | | \$3.00 | \$3.00 | \$3.00 | \$3.00 | 0.00% |
| 1 | J9207 | injection, ixabepilone, 1 mg | | 0-999 | N/F | | \$122.55 | \$122.55 | \$128.07 | \$128.07 | 4.50% |
| 1 | J9208 | injection, ifosfamide, 1 gram | | 0-999 | N/F | | \$25.38 | \$25.38 | \$26.75 | \$26.75 | 5.40% |
| 1 | J9209 | injection, mesna, 200 mg | | 0-999 | N/F | | \$1.67 | \$1.67 | \$1.37 | \$1.37 | -17.96% |

CFR Attachment A(8) - Physician Administered Drugs Oncology (Proposed to be effective September 1, 2024)

| TOS* | Procedure Code | Long Description | Modifier 1 | Age Range | Non-Facility (N)/ Facility | Provider Type/ Provider Specialty | CURRENT | | 9/1/2024 | | Percent Change from Current Medicaid |
|------|----------------|--|------------|-----------|----------------------------|-----------------------------------|----------------------|-------------------------------|-----------------------|--------------------------------|--------------------------------------|
| | | | | | | | Current Medicaid Fee | Current Adjusted Medicaid Fee | Proposed Medicaid Fee | Proposed Adjusted Medicaid Fee | |
| 1 | J9211 | injection, idarubicin hydrochloride, 5 mg | | 0-999 | N/F | | \$33.90 | \$33.90 | \$33.90 | \$33.90 | 0.00% |
| 1 | J9214 | injection, interferon, alfa-2b, recombinant, 1 million units | | 0-999 | N/F | | \$32.57 | \$32.57 | \$32.57 | \$32.57 | 0.00% |
| 1 | J9217 | leuprolide acetate (for depot suspension), 7.5 mg | | 0-999 | N/F | | \$165.86 | \$165.86 | \$181.30 | \$181.30 | 9.31% |
| 1 | J9218 | leuprolide acetate, per 1 mg | | 0-999 | N/F | | \$10.06 | \$10.06 | \$10.06 | \$10.06 | 0.00% |
| 1 | J9223 | injection, lurbinectedin, 0.1 mg | | 0-999 | N/F | | \$197.18 | \$197.18 | \$200.01 | \$200.01 | 1.44% |
| 1 | J9227 | injection, isatuximab-irfc, 10 mg | | 0-999 | N/F | | \$74.35 | \$74.35 | \$76.50 | \$76.50 | 2.89% |
| 1 | J9228 | injection, ipilimumab, 1 mg | | 0-999 | N/F | | \$167.93 | \$167.93 | \$172.42 | \$172.42 | 2.67% |
| 1 | J9229 | injection, inotuzumab ozogamicin, 0.1 mg | | 0-999 | N/F | | \$2,529.55 | \$2,529.55 | \$2,580.15 | \$2,580.15 | 2.00% |
| 1 | J9245 | injection, melphalan hydrochloride, not otherwise specified, 50 mg | | 0-999 | N/F | | \$154.19 | \$154.19 | \$148.02 | \$148.02 | -4.00% |
| 1 | J9246 | injection, melphalan (evomela), 1 mg | | 0-999 | N/F | | \$16.44 | \$16.44 | \$16.49 | \$16.49 | 0.30% |
| 1 | J9250 | methotrexate sodium, 5 mg | | 0-999 | N/F | | \$0.27 | \$0.27 | \$0.31 | \$0.31 | 14.81% |
| 1 | J9260 | methotrexate sodium, 50 mg | | 0-999 | N/F | | \$2.71 | \$2.71 | \$3.03 | \$3.03 | 11.81% |
| 1 | J9262 | injection, omacetaxine mepesuccinate, 0.01 mg | | 0-999 | N/F | | \$4.01 | \$4.01 | \$3.96 | \$3.96 | -1.25% |
| 1 | J9263 | injection, oxaliplatin, 0.5 mg | | 0-999 | N/F | | \$0.07 | \$0.07 | \$0.07 | \$0.07 | 0.00% |
| 1 | J9264 | injection, paclitaxel protein-bound particles, 1 mg | | 0-999 | N/F | | \$12.06 | \$12.06 | \$12.06 | \$12.06 | 0.00% |
| 1 | J9266 | injection, pegaspargase, per single dose vial | | 0-999 | N/F | | \$25,762.46 | \$25,762.46 | \$25,781.46 | \$25,781.46 | 0.07% |
| 1 | J9267 | injection, paclitaxel, 1 mg | | 0-999 | N/F | | \$0.12 | \$0.12 | \$0.11 | \$0.11 | -8.33% |
| 1 | J9268 | injection, pentostatin, 10 mg | | 0-999 | N/F | | \$2,387.73 | \$2,387.73 | \$2,273.15 | \$2,273.15 | -4.80% |
| 1 | J9269 | injection, tagraxofusp-erzs, 10 micrograms | | 0-999 | N/F | | \$322.60 | \$322.60 | \$325.56 | \$325.56 | 0.92% |
| 1 | J9271 | injection, pembrolizumab, 1 mg | | 0-999 | N/F | | \$54.81 | \$54.81 | \$55.73 | \$55.73 | 1.68% |
| 1 | J9272 | injection, dostarlimab-qxly, 10 mg | | 0-999 | N/F | | \$226.93 | \$226.93 | \$233.26 | \$233.26 | 2.79% |
| 1 | J9273 | injection, tisotumab vedotin-tftv, 1 mg | | 0-999 | N/F | | \$162.05 | \$162.05 | \$168.31 | \$168.31 | 3.86% |
| 1 | J9274 | injection, tebentafusp-tebn, 1 microgram | | 0-999 | N/F | | \$203.83 | \$203.83 | \$208.93 | \$208.93 | 2.50% |
| 1 | J9280 | injection, mitomycin, 5 mg | | 0-999 | N/F | | \$44.47 | \$44.47 | \$44.47 | \$44.47 | 0.00% |
| 1 | J9281 | mitomycin pyelocalyceal instillation, 1 mg | | 0-999 | N/F | | \$296.17 | \$296.17 | \$300.75 | \$300.75 | 1.55% |
| 1 | J9285 | injection, olaratumab, 10 mg | | 0-999 | N/F | | \$52.07 | \$52.07 | \$52.07 | \$52.07 | 0.00% |
| 1 | J9293 | injection, mitoxantrone hydrochloride, per 5 mg | | 0-999 | N/F | | \$54.88 | \$54.88 | \$43.58 | \$43.58 | -20.59% |
| 1 | J9294 | injection, pemetrexed (hospira) not therapeutically equivalent to J9305, 10 mg | | 0-999 | N/F | | \$10.46 | \$10.46 | \$10.55 | \$10.55 | 0.86% |
| 1 | J9295 | injection, necitumumab, 1 mg | | 0-999 | N/F | | \$5.74 | \$5.74 | \$5.74 | \$5.74 | 0.00% |
| 1 | J9296 | injection, pemetrexed (accord) not therapeutically equivalent to J9305, 10 mg | | 0-999 | N/F | | \$9.74 | \$9.74 | \$10.93 | \$10.93 | 12.22% |
| 1 | J9297 | injection, pemetrexed (sandoz), not therapeutically equivalent to J9305, 10 mg | | 0-999 | N/F | | \$9.16 | \$9.16 | \$9.16 | \$9.16 | 0.00% |
| 1 | J9298 | injection, nivolumab and relatimab-rmbw, 3 mg/1 mg | | 0-999 | N/F | | \$183.63 | \$183.63 | \$187.15 | \$187.15 | 1.92% |
| 1 | J9299 | injection, nivolumab, 1 mg | | 0-999 | N/F | | \$30.46 | \$30.46 | \$31.09 | \$31.09 | 2.07% |
| 1 | J9301 | injection, obinutuzumab, 10 mg | | 0-999 | N/F | | \$70.55 | \$70.55 | \$70.34 | \$70.34 | -0.30% |
| 1 | J9302 | injection, ofatumumab, 10 mg | | 0-999 | N/F | | \$72.40 | \$72.40 | \$72.40 | \$72.40 | 0.00% |
| 1 | J9303 | injection, panitumumab, 10 mg | | 0-999 | N/F | | \$149.71 | \$149.71 | \$150.66 | \$150.66 | 0.63% |
| 1 | J9304 | injection, pemetrexed (pemfexy), 10 mg | | 0-999 | N/F | | \$64.48 | \$64.48 | \$62.32 | \$62.32 | -3.35% |

CFR Attachment A(8) - Physician Administered Drugs Oncology (Proposed to be effective September 1, 2024)

| TOS* | Procedure Code | Long Description | Modifier 1 | Age Range | Non-Facility (N)/ Facility | Provider Type/ Provider Specialty | CURRENT | | 9/1/2024 | | Percent Change from Current Medicaid |
|------|----------------|--|------------|-----------|----------------------------|-----------------------------------|----------------------|-------------------------------|-----------------------|--------------------------------|--------------------------------------|
| | | | | | | | Current Medicaid Fee | Current Adjusted Medicaid Fee | Proposed Medicaid Fee | Proposed Adjusted Medicaid Fee | |
| 1 | J9305 | injection, pemetrexed, not otherwise specified, 10 mg | | 0-999 | N/F | | \$7.93 | \$7.93 | \$4.37 | \$4.37 | -44.89% |
| 1 | J9306 | injection, pertuzumab, 1 mg | | 0-999 | N/F | | \$15.37 | \$15.37 | \$15.43 | \$15.43 | 0.39% |
| 1 | J9307 | injection, pralatrexate, 1 mg | | 0-999 | N/F | | \$356.51 | \$356.51 | \$289.14 | \$289.14 | -18.90% |
| 1 | J9309 | injection, polatuzumab vedotin-piia, 1 mg | | 0-999 | N/F | | \$121.25 | \$121.25 | \$124.29 | \$124.29 | 2.51% |
| 1 | J9311 | injection, rituximab 10 mg and hyaluronidase | | 0-999 | N/F | | \$37.46 | \$37.46 | \$37.41 | \$37.41 | -0.13% |
| 1 | J9312 | injection, rituximab, 10 mg | | 0-999 | N/F | | \$81.04 | \$81.04 | \$79.20 | \$79.20 | -2.27% |
| 1 | J9313 | injection, moxetumomab pasudotox-tdfk, 0.01 mg | | 0-999 | N/F | | \$23.39 | \$23.39 | \$23.39 | \$23.39 | 0.00% |
| 1 | J9314 | injection, pemetrexed (teva) not therapeutically equivalent to J9305, 10 mg | | 0-999 | N/F | | \$12.30 | \$12.30 | \$12.30 | \$12.30 | 0.00% |
| 1 | J9316 | injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg | | 0-999 | N/F | | \$68.21 | \$68.21 | \$67.05 | \$67.05 | -1.70% |
| 1 | J9316 | injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg | | 18-999 | N/F | | \$68.21 | \$68.21 | \$67.05 | \$67.05 | -1.70% |
| 1 | J9317 | injection, sacituzumab govitecan-hziy, 2.5 mg | | 0-999 | N/F | | \$33.32 | \$33.32 | \$34.08 | \$34.08 | 2.28% |
| 1 | J9318 | injection, romidepsin, non-lyophilized, 0.1 mg | | 0-999 | N/F | | \$38.38 | \$38.38 | \$38.38 | \$38.38 | 0.00% |
| 1 | J9319 | injection, romidepsin, lyophilized, 0.1 mg | | 0-999 | N/F | | \$30.37 | \$30.37 | \$31.96 | \$31.96 | 5.24% |
| 1 | J9320 | injection, streptozocin, 1 gram | | 0-999 | N/F | | \$370.18 | \$370.18 | \$419.08 | \$419.08 | 13.21% |
| 1 | J9323 | injection, pemetrexed (hospira) not therapeutically equivalent to J9305, 10 mg | | 0-999 | N/F | | \$11.81 | \$11.81 | \$6.01 | \$6.01 | -49.11% |
| 1 | J9325 | injection, talimogene laherparepvec, per 1 million plaque forming units | | 0-999 | N/F | | \$62.68 | \$62.68 | \$66.59 | \$66.59 | 6.24% |
| 1 | J9328 | injection, temozolomide, 1 mg | | 0-999 | N/F | | \$10.41 | \$10.41 | \$10.40 | \$10.40 | -0.10% |
| 1 | J9330 | injection, temsirolimus, 1 mg | | 0-999 | N/F | | \$33.64 | \$33.64 | \$30.99 | \$30.99 | -7.88% |
| 1 | J9331 | injection, sirolimus protein-bound particles, 1 mg | | 0-999 | N/F | | \$85.12 | \$85.12 | \$109.29 | \$109.29 | 28.40% |
| 1 | J9340 | injection, thiotepa, 15 mg | | 0-999 | N/F | | \$259.56 | \$259.56 | \$251.21 | \$251.21 | -3.22% |
| 1 | J9347 | injection, tremelimumab-actl, 1 mg | | 0-999 | N/F | | \$136.56 | \$136.56 | \$136.09 | \$136.09 | -0.34% |
| 1 | J9348 | injection, naxitamab-ggqk, 1 mg | | 0-999 | N/F | | \$658.17 | \$658.17 | \$609.77 | \$609.77 | -7.35% |
| 1 | J9349 | injection, tafasitamab-cxix, 2 mg | | 0-999 | N/F | | \$13.30 | \$13.30 | \$13.60 | \$13.60 | 2.26% |
| 1 | J9350 | injection, tepizumab-mzwv, 5 mcg | | 0-999 | N/F | | \$712.87 | \$712.87 | \$629.64 | \$629.64 | -11.68% |
| 1 | J9351 | injection, topotecan, 0.1 mg | | 0-999 | N/F | | \$0.82 | \$0.82 | \$0.78 | \$0.78 | -4.88% |
| 1 | J9352 | injection, trabectedin, 0.1 mg | | 0-999 | N/F | | \$337.28 | \$337.28 | \$338.40 | \$338.40 | 0.33% |
| 1 | J9353 | injection, margetuximab-cmkb, 5 mg | | 0-999 | N/F | | \$45.88 | \$45.88 | \$47.05 | \$47.05 | 2.55% |
| 1 | J9354 | injection, ado-trastuzumab emtansine, 1 mg | | 0-999 | N/F | | \$38.33 | \$38.33 | \$38.37 | \$38.37 | 0.10% |
| 1 | J9355 | injection, trastuzumab, excludes biosimilar, 10 mg | | 0-999 | N/F | | \$81.08 | \$81.08 | \$80.47 | \$80.47 | -0.75% |
| 1 | J9356 | injection, trastuzumab, 10 mg and hyaluronidase-oysk | | 0-999 | N/F | | \$65.58 | \$65.58 | \$66.02 | \$66.02 | 0.67% |
| 1 | J9357 | injection, valrubicin, intravesical, 200 mg | | 0-999 | N/F | | \$1,391.80 | \$1,391.80 | \$1,363.85 | \$1,363.85 | -2.01% |
| 1 | J9358 | injection, fam-trastuzumab deruxtecan-nxki, 1 mg | | 0-999 | N/F | | \$26.24 | \$26.24 | \$27.24 | \$27.24 | 3.81% |
| 1 | J9359 | injection, loncastuximab tesirine-lpyl, 0.075 mg | | 0-999 | N/F | | \$196.45 | \$196.45 | \$200.63 | \$200.63 | 2.13% |
| 1 | J9360 | injection, vinblastine sulfate, 1 mg | | 0-999 | N/F | | \$3.95 | \$3.95 | \$4.22 | \$4.22 | 6.84% |
| 1 | J9370 | vincristine sulfate, 1 mg | | 0-999 | N/F | | \$4.94 | \$4.94 | \$4.94 | \$4.94 | 0.00% |
| 1 | J9371 | injection, vincristine sulfate liposome, 1 mg | | 0-999 | N/F | | \$4,127.21 | \$4,127.21 | \$4,127.21 | \$4,127.21 | 0.00% |

CFR Attachment A(8) - Physician Administered Drugs Oncology (Proposed to be effective September 1, 2024)

| TOS* | Procedure Code | Long Description | Modifier 1 | Age Range | Non-Facility (N)/ Facility | Provider Type/ Provider Specialty | CURRENT | | 9/1/2024 | | Percent Change from Current Medicaid |
|------|----------------|--|------------|-----------|----------------------------|-----------------------------------|----------------------|-------------------------------|-----------------------|--------------------------------|--------------------------------------|
| | | | | | | | Current Medicaid Fee | Current Adjusted Medicaid Fee | Proposed Medicaid Fee | Proposed Adjusted Medicaid Fee | |
| 1 | J9380 | injection, tepilizumab-mzwv, 5 mcg | | 0-999 | N/F | | \$30.94 | \$30.94 | \$30.85 | \$30.85 | -0.29% |
| 1 | J9390 | injection, vinorelbine tartrate, 10 mg | | 0-999 | N/F | | \$8.27 | \$8.27 | \$7.42 | \$7.42 | -10.28% |
| 1 | J9393 | injection, fulvestrant (teva) not therapeutically equivalent to J9395, 25 mg | | 0-999 | N/F | | \$21.20 | \$21.20 | \$21.20 | \$21.20 | 0.00% |
| 1 | J9394 | injection, fulvestrant (fresenius kabi) not therapeutically equivalent to J9395, 25 mg | | 0-999 | N/F | | \$1.65 | \$1.65 | \$1.65 | \$1.65 | 0.00% |
| 1 | J9395 | injection, fulvestrant, 25 mg | | 0-999 | N/F | | \$9.47 | \$9.47 | \$8.45 | \$8.45 | -10.77% |
| 1 | J9400 | injection, ziv-aflibercept, 1 mg | | 0-999 | N/F | | \$6.81 | \$6.81 | \$7.28 | \$7.28 | 6.90% |
| 1 | M0245 | intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | | 0-999 | N/F | | \$450.00 | \$450.00 | \$450.00 | \$450.00 | 0.00% |
| 1 | Q0138 | injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | | 0-999 | N/F | | \$0.50 | \$0.50 | \$0.36 | \$0.36 | -28.00% |
| 1 | Q2041 | axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose | | 0-999 | N/F | | \$449,440.00 | \$449,440.00 | \$449,440.00 | \$449,440.00 | 0.00% |
| 1 | Q2042 | tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose | | 0-999 | N/F | | \$449,440.00 | \$449,440.00 | \$511,072.50 | \$511,072.50 | 13.71% |
| 1 | Q2042 | tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose | U1 | 0-999 | N/F | | \$652,593.00 | \$652,593.00 | \$652,593.00 | \$652,593.00 | 0.00% |
| 1 | Q2043 | sipuleucel-t, minimum of 50 million autologous cd54+ cells activated with pap-gm-csf, including leukapheresis and all other preparatory procedures, per infusion | | 0-999 | N/F | | \$53,062.44 | \$53,062.44 | \$53,426.66 | \$53,426.66 | 0.69% |
| 1 | Q2050 | injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10mg | | 0-999 | N/F | | \$87.98 | \$87.98 | \$85.48 | \$85.48 | -2.84% |
| 1 | Q2053 | brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose | | 0-999 | N/F | | \$449,440.00 | \$449,440.00 | \$449,440.00 | \$449,440.00 | 0.00% |
| 1 | Q2054 | lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose | | 0-999 | N/F | | \$536,672.40 | \$536,672.40 | \$473,853.52 | \$473,853.52 | -11.71% |
| 1 | Q2055 | idecabtagene vicleucel, up to 460 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose | | 0-999 | N/F | | \$548,706.00 | \$548,706.00 | \$484,690.30 | \$484,690.30 | -11.67% |

CFR Attachment A(8) - Physician Administered Drugs Oncology (Proposed to be effective September 1, 2024)

| TOS* | Procedure Code | Long Description | Modifier 1 | Age Range | Non-Facility (N)/ Facility | Provider Type/ Provider Specialty | CURRENT | | 9/1/2024 | | Percent Change from Current Medicaid |
|------|----------------|--|------------|-----------|----------------------------|-----------------------------------|----------------------|-------------------------------|-----------------------|--------------------------------|--------------------------------------|
| | | | | | | | Current Medicaid Fee | Current Adjusted Medicaid Fee | Proposed Medicaid Fee | Proposed Adjusted Medicaid Fee | |
| 1 | Q2056 | ciltacabtagene autoleucl, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose | | 0-999 | N/F | | \$574,740.00 | \$574,740.00 | \$507,195.92 | \$507,195.92 | -11.75% |
| 1 | Q5107 | injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | | 0-999 | N/F | | \$28.40 | \$28.40 | \$25.62 | \$25.62 | -9.79% |
| 1 | Q5112 | injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg | | 0-999 | N/F | | \$46.93 | \$46.93 | \$38.94 | \$38.94 | -17.03% |
| 1 | Q5113 | injection, trastuzumab-pkrb, biosimilar, (herzuma), 10 mg | | 0-999 | N/F | | \$29.87 | \$29.87 | \$29.87 | \$29.87 | 0.00% |
| 1 | Q5114 | injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg | | 0-999 | N/F | | \$40.41 | \$40.41 | \$44.43 | \$44.43 | 9.95% |
| 1 | Q5115 | injection, rituximab-abbs, biosimilar, (truxima), 10 mg | | 0-999 | N/F | | \$39.79 | \$39.79 | \$35.89 | \$35.89 | -9.80% |
| 1 | Q5116 | injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg | | 0-999 | N/F | | \$23.15 | \$23.15 | \$16.37 | \$16.37 | -29.29% |
| 1 | Q5117 | injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg | | 0-999 | N/F | | \$23.96 | \$23.96 | \$13.45 | \$13.45 | -43.86% |
| 1 | Q5118 | injection, bevacizumab-bvcr, biosimilar, (zirabev), 10 mg | | 0-999 | N/F | | \$28.19 | \$28.19 | \$21.51 | \$21.51 | -23.70% |
| 1 | Q5119 | injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | | 0-999 | N/F | | \$27.51 | \$27.51 | \$20.45 | \$20.45 | -25.66% |
| 1 | Q5120 | injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg | | 0-999 | N/F | | \$30.05 | \$30.05 | \$30.05 | \$30.05 | 0.00% |
| 1 | Q5122 | injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | | 0-999 | N/F | | \$101.89 | \$101.89 | \$62.38 | \$62.38 | -38.78% |
| 1 | Q5123 | injection, rituximab-arrx, biosimilar, (riabni), 10 mg | | 0-999 | N/F | | \$44.58 | \$44.58 | \$41.42 | \$41.42 | -7.09% |
| 1 | Q5126 | injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg | | 0-999 | N/F | | \$72.52 | \$72.52 | \$60.58 | \$60.58 | -16.46% |

| *Type of Service (TOS) | |
|------------------------|---|
| 1 | Medical Services |
| 9 | Other Medical Items or Services |
| D | Tuberculosis Clinic |
| Provider Type | |
| 72 | Nephrology (Hemodialysis, Renal Dialysis) |
| 73 | Renal Dialysis Facility |

** Required Notice: The five-character code included in this notice is obtained from the Current Procedural Terminology (CPT®), copyright 2024 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physicians. The responsibility for the content of this notice is with HHSC and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in this notice. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained.